Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival

Anticancer Res. 2014 May;34(5):2517-23.

Abstract

Aim: We evaluated the relationship of early metabolic responses on (18)F-fluorodeoxyglucose-positron-emission tomography/computed tomography (PET/CT) performed within one month after concurrent chemoradiotherapy (CCRT) with local tumor control and survival in patients with advanced stage III non-small cell lung cancer (NSCLC).

Patients and methods: One hundred and nineteen patients with unresectable stage III NSCLC who completed definitive CCRT were included. PET/CT was performed 2-4 weeks after completion of radiotherapy.

Results: The maximum standardized uptake value (SUVmax) reduction ratio of the primary lesion (primary SRR, 80%, p<0.001), gross tumor volume (150 cm(3), p=0.036), and pre-radiotherapy ratio of SUVmax of the metastatic lymph node to that of the primary lesion (60%, p=0.05) were significantly associated with OS in multivariate analysis. The primary SRR was the only statistically significant parameter for local control.

Conclusion: Early metabolic response of the primary lesion after CCRT correlated with local control and overall survival in patients with unresectable stage III NSCLC.

Keywords: Non-small cell lung cancer; concurrent chemoradiotherapy; metabolic response; prognosis.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging*
  • Carcinoma, Non-Small-Cell Lung / mortality*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Chemoradiotherapy
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Kaplan-Meier Estimate
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / mortality*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Multimodal Imaging
  • Neoplasm Staging
  • Positron-Emission Tomography
  • Proportional Hazards Models
  • Radiopharmaceuticals
  • Retrospective Studies
  • Tomography, X-Ray Computed

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18